Relevant bibliographies by topics / Anxiolytics / Books
To see the other types of publications on this topic, follow the link: Anxiolytics.

Books on the topic 'Anxiolytics'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Anxiolytics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Briley, Mike, and David Nutt, eds. Anxiolytics. Basel: Birkhäuser Basel, 2000. http://dx.doi.org/10.1007/978-3-0348-8470-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Workshop on "Target Receptors for Anxiolytics and Hypnotics: From Molecular Pharmacology to Therapeutics" (1991 Monte-Carlo, Monaco). Target receptors for anxiolytics and hypnotics: From molecular pharmacology to therapeutics : Workshop on "Target Receptors for Anxiolytics and Hypnotics: From Molecular Pharmacology to Therapeutics," Monte Carlo, November 24-26, 1991. Edited by Mendlewicz J and Racagni Giorgio. Basel: Karger, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stephens, David N., ed. Anxiolytic β-Carbolines. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78451-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

1956-, Masotto Claudio, and Steardo Luca 1947-, eds. Pharmacology of anxiolytic drugs. Seattle: Hogrefe & Huber, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Holsboer, Florian, and Andreas Ströhle, eds. Anxiety and Anxiolytic Drugs. Berlin/Heidelberg: Springer-Verlag, 2005. http://dx.doi.org/10.1007/3-540-28082-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

J, Sramek John, and Kurtz Neil M, eds. Anxiolytic compounds: Perspectives in drug development. Chichester: John Wiley, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Boer, Sietse Freerk De. Dynamics of stress hormones in the rat: Modification by psychological factors and anxiolytic drugs = De dynamiek van stress hormonen bij de rat : modificatie door psychologische factoren en anxiolytica. [Utrecht, The Netherlands]: S.F. de Boer, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Briley, Mike. Anxiolytics. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Buschmann, Helmut, José Luis Díaz, Jörg Holenz, Antonio Párraga, Antoni Torrens, and José Miguel Vela, eds. Antidepressants, Antipsychotics, Anxiolytics. Wiley, 2007. http://dx.doi.org/10.1002/9783527619337.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

(Editor), Mike Briley, and David Nutt (Editor), eds. Anxiolytics (Milestones in Drug Therapy). Birkhauser, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

E, File S., ed. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

E, File Sandra, ed. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Psychopharmacology of Anxiolytics and Antidepressants. Elsevier, 1991. http://dx.doi.org/10.1016/c2009-0-00830-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Nutt, D. J., and W. B. Mendelson. Hypnotics and Anxiolytics (Bailliere's Clinical Psychiatry). Elsevier, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Association, American Psychiatric. Pocket Guide to Medications: Anxiolytics, Mood Stabilizers, and ADHD. American Psychiatric Association Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Hoffmeister, F., and G. Stille. Psychotropic Agents : Part II: Anxiolytics, Gerontopsychopharmacological Agents, and Psychomotor Stimulants. Springer-Verlag Berlin Heidelberg New York, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

(Editor), Helmut Buschmann, Jörg Holenz (Editor), Antonio Párraga (Editor), Antoni Torrens (Editor), José Miguel Vela (Editor), and José Luis Díaz (Editor), eds. Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Istituto superiore di sanità (Italy), ed. Non-benzodiazepine anxiolytics and hypnotics: Symposium, Istituto superiore di sanità : abstract book. Rome: Istituto superiore di sanità, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Harrison, Mark. Central nervous system. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198765875.003.0041.

Full text
Abstract:
This chapter describes the pharmacology of the central nervous system as it applies to Emergency Medicine, and in particular the Primary FRCEM examination. The chapter outlines the key details of hypnotics and anxiolytics, antipsychotics, antimania drugs, tricyclic antidepressants, nausea and vomiting, analgesics, non-opioid analgesics, opioid analgesics, antiepileptics, and status epilepticus. This chapter is laid out exactly following the RCEM syllabus, to allow easy reference and consolidation of learning.
APA, Harvard, Vancouver, ISO, and other styles
20

Mendlewicz, J. Target Receptors for Anxiolytics and Hypnotics: From Molecular Pharmacology to Therapeutics (International Academy for Biomedical and Drug Research). S Karger Pub, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Stewart, Jessica Ann, L. Mark Russakoff, and Jonathan W. Stewart. Pharmacotherapy, ECT, and TMS. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199326075.003.0016.

Full text
Abstract:
Physicians’ attention to patients’ concerns and attitudes about taking medication will engender adherence, as will close monitoring of potentially disconcerting side effects. The primary indication for antipsychotic medications is the treatment of psychotic disorders and mania, even in the absence of psychosis. The more troublesome side effects of antipsychotic medications include increased appetite and weight gain; extrapyramidal side effects, tardive dyskinesia, and neuroleptic malignant syndrome. Antidepressants are effective for treating depressive illness, including major depression, persistent depressive disorder (dysthymia) and premenstrual dysphoric disorder. They are also often used effectively in the treatment of anxiety disorders, obsessive-compulsive disorder, bulimia nervosa, and somatic symptom disorders. Selective serotonin reuptake inhibitors (SSRIs) are generally well tolerated. Other important categories of medications include mood stabilizers and anxiolytics.
APA, Harvard, Vancouver, ISO, and other styles
22

Rees, Gayla, Benjamin Shapiro, and Matthew Torrington. Integrative Approach to Sedative-Hypnotic Use Disorder. Edited by Shahla J. Modir and George E. Muñoz. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190275334.003.0005.

Full text
Abstract:
Sedatives, hypnotics, and anxiolytics are CNS depressants with GABAergic activity that are potentially habit-forming due to their activity in brain reward pathways. They are central in the drug overdose epidemic with benzodiazepines (BZD) being involved in approximately 31% of all fatal overdoses. There are 4 withdrawal syndromes: High dose minor and major withdrawal, low dose withdrawal, and protracted withdrawal. Benzodiazepines are chemically related positive allosteric modulators of the GABA at the GABA-A receptor. In differential expression 5 different receptor subunits play a role in acute and prolonged withdrawal syndromes. Benzodiazepines have supplanted barbiturates for treatment of anxiety and insomnia due to their wider therapeutic index. Barbiturates can be helpful managing opiate and benazodiazapeine withdrawal. Traditional Chinese Medicine can improve hypnotics-dependent insomnia. Mindfulness-based relapse prevention and yoga may offer benefits but are poorly studied.
APA, Harvard, Vancouver, ISO, and other styles
23

Holsboer, Florian, and Andreas Ströhle. Anxiety and Anxiolytic Drugs. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Wheatley, David. Anxiolytic Jungle: Where Next. John Wiley & Sons, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Vázquez, Gustavo H., Alberto Forte, Sebastián Camino, Leonardo Tondo, and Ross J. Baldessarini. Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0017.

Full text
Abstract:
Anxiety symptoms and syndromes affect approximately half of both types I and II bipolar disorder (BD) patients at some time, more in women than men. Reported prevalence has ranked: generalized anxiety ≥ phobias ≥ panic ≥ post-traumatic stress syndrome ≥ obsessive–compulsive syndrome. BD associated with anxiety disorders is less responsive to mood-stabilizing treatments, with greater disability, substance abuse, and possibly suicidal risk. Emerging treatments for anxiety in BD patients include lurasidone, olanzapine, quetiapine, valproate, and psychotherapies, whereas the efficacy and safety of standard anxiolytics and antidepressants are not established. Abuse of alcohol, cannabis, stimulants, and opioids, alone or in combinations, also affects about half of BD patients at some time—more men than women and possibly somewhat more in type I than II. Substance abuse greatly complicates clinical care, contributing to erratic treatment-adherence, adverse outcomes, disability, increased risk of suicide or accidental death, and increased costs of care and from disability.
APA, Harvard, Vancouver, ISO, and other styles
26

Casey, Patricia. Treatment of adjustment disorders (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198786214.003.0007.

Full text
Abstract:
There are few randomized controlled studies of the treatment of AD. This is due to the transience of the symptoms, the difficulty obtaining a homogeneous population owing to the absence of diagnostic criteria, and the variable nature of the stressor, among others. Clinical guidelines specify that brief psychological interventions are preferred, and these incorporate elements from the many approaches now available on the assumption that their mechanism of action will also be effective in AD. Few have been tested specifically in AD. Low-intensity therapies specific to AD are being developed, such as biblio-therapy and online self-help. Pharmacological interventions have not been tested in quality trials, but despite this, antidepressants continue to be frequently prescribed. A few trials of anxiolytics have found some benefit for all the agents examined, but none used placebo. EMDR was found to be beneficial in a small pilot study and is worthy of further study.
APA, Harvard, Vancouver, ISO, and other styles
27

Feinstein, Robert E., and Brian Rothberg. Violence. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199326075.003.0013.

Full text
Abstract:
Potentially violent patients need immediate attention and evaluation to determine their risk of imminent violence. A past history of violence is the best predictor of future violent behavior, and individuals who have committed violent acts in the past and have been arrested for assaultive behavior represent the highest risk; people who carry weapons or have access to weapons are of relatively high risk. Individuals with violent impulses who are either intoxicated or are in withdrawal have the most extreme risk for imminent violence. The treatment of acute aggression or agitation involves the judicious use of sedative-anxiolytics or low doses of second-generation antipsychotics. SSRIs have been used to treat aggressive, impulsive, and violent symptoms, particularly in individuals with head injuries, and lithium carbonate can reduce impulsive aggression to extremely low levels in some aggressive patients. Two Tarasoff decisions have become national standards for clinical practice regarding “duty to warn” and “duty to protect” all potential victims of life-threatening danger from a homicidal patient.
APA, Harvard, Vancouver, ISO, and other styles
28

1919-, Wheatley David, ed. The Anxiolytic jungle: Where next? Chichester, West Sussex, England: Wiley, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

(Editor), Florian Holsboer, and Andreas Ströhle (Editor), eds. Anxiety and Anxiolytic Drugs (Handbook of Experimental Pharmacology). Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Stephens, David N., and Hiroshi Maeda. Anxiolytic ? -Carbolines: From Molecular Biology to the Clinic. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Anxiety and Anxiolytic Drugs. Springer, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Does body temperature mediate anxiolytic effects of acute exercise? 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

1946-, Stephens David N., ed. Anxiolytic [Beta]-carbolines: From molecular biology to the clinic. Berlin: Springer-Verlag, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Does body temperature mediate anxiolytic effects of acute exercise? 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Stephens, David N. Anxiolytic B-Carbolines: From Molecular Biology to the Clinic (Psychopharmacology Series). Springer-Verlag Telos, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Parker, Philip M. The 2007-2012 World Outlook for Prescription Barbituate Anxiolytic and Hypnotic Sedatives. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

The 2006-2011 World Outlook for Prescription Barbituate Anxiolytic and Hypnotic Sedatives. Icon Group International, Inc., 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sinha, Shirshendu. Substance-Related Disorders. Edited by Rajiv Radhakrishnan and Lily Arora. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190265557.003.0016.

Full text
Abstract:
This chapter reviews topics on substance-related disorders including alcohol-related disorders, stimulant-related disorders, caffeine-related disorders, cannabis-related disorders, stimulant-related disorders, hallucinogen-related disorders, tobacco-related disorders, opioid-related disorders, phencyclidine-related disorders and sedative-, hypnotic-, or anxiolytic-related disorders
APA, Harvard, Vancouver, ISO, and other styles
39

Parker, Philip M. The 2007-2012 Outlook for Prescription Barbituate Anxiolytic and Hypnotic Sedatives in Japan. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
40

Barnes, Janine Margaret. Neurochemical assessments of the actions of novel agents having nootropic and anxiolytic potential. Bradford, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

Parker, Philip M. The 2007-2012 Outlook for Prescription Non-Barbituate Anxiolytic and Hypnotic Sedatives in Japan. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
42

Parker, Philip M. The 2007-2012 Outlook for Prescription Barbituate Anxiolytic and Hypnotic Sedatives in Greater China. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Parker, Philip M. The 2007-2012 Outlook for Prescription Non-Barbituate Anxiolytic and Hypnotic Sedatives in India. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Gath, Dennis, and Laurence Mynors-Wallis. Problem-solving treatment in primary care. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780192627254.003.0017.

Full text
Abstract:
Chapter 17 discusses problem-solving treatment in primary care and outlines a series of studies into the treatment of emotional disorders in primary care, including the effects of not prescribing anxiolytic medication for emotional disorders, the feasibility and efficacy of problem-solving for emotional disorders and poor prognosis treatment, problem-solving treatment for major depression in general practice, further evaluation of problem-solving treatment for major depression in primary care.
APA, Harvard, Vancouver, ISO, and other styles
45

Parker, Philip M. The 2007-2012 Outlook for Prescription Barbituate Anxiolytic and Hypnotic Sedatives in the United States. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Parker, Philip M. The 2007-2012 Outlook for Prescription Non-Barbituate Anxiolytic and Hypnotic Sedatives in Greater China. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
47

Parker, Philip M. The 2007-2012 Outlook for Prescription Non-Barbituate Anxiolytic and Hypnotic Sedatives in the United States. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
48

Parker, Philip M. The 2007-2012 Outlook for Non-Prescription Anxiolytic, Hypnotic, and Sleep-Inducing Sedatives Excluding Antihistamines in India. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Parker, Philip M. The 2007-2012 Outlook for Non-Prescription Anxiolytic, Hypnotic, and Sleep-Inducing Sedatives Excluding Antihistamines in Japan. ICON Group International, Inc., 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Venuto, Charles S., and Karl Kieburtz. Huntington Disease. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0008.

Full text
Abstract:
The clinical management of Huntington’s disease entails pharmacologic interventions and nonpharmacologic supportive therapy. There are no treatments that can halt or alter the progression of disease, therefore the goal is to maximize function and optimize quality of life. Tetrabenazine is the only pharmacologic agent with regulatory approval for Huntington’s disease chorea; however, off-label use of antidopaminergic agents is common. Treatment of behavioral disturbances can be tailored to the specific symptoms by using antidepressant, antipsychotic, and anxiolytic agents. Clinical trials testing therapeutic strategies for motor, behavioral, and cognitive aspects of disease and delaying progression are ongoing.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Anxiolytics' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography